UY28458A1 - Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - Google Patents
Compuestos de oxazol para el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- UY28458A1 UY28458A1 UY28458A UY28458A UY28458A1 UY 28458 A1 UY28458 A1 UY 28458A1 UY 28458 A UY28458 A UY 28458A UY 28458 A UY28458 A UY 28458A UY 28458 A1 UY28458 A1 UY 28458A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- treatment
- neurodegenerative disorders
- formula
- oxazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de Fórmula en donde R3, R5, R7 y Z, así como otros valores enumerados con relación a R3, R5, R6, R7 y Z son como se los define. Loscompuestos de Fórmula I presentan actividad inhibidora de la producción de péptido AB. Esta invención se refiere además a composiciones farmacéuticas y métodos para tratar enfermedades, por ejemplo, enfermedades neurodegenerativas, i.e. enfermedad de Alzheimer, en un mamífero, que comprende compuestos de Fórmula I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49288403P | 2003-08-06 | 2003-08-06 | |
| US49802803P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28458A1 true UY28458A1 (es) | 2005-03-31 |
Family
ID=34197958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28458A UY28458A1 (es) | 2003-08-06 | 2004-08-06 | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7112599B2 (es) |
| EP (1) | EP1653952A4 (es) |
| JP (1) | JP2007501244A (es) |
| AR (1) | AR046327A1 (es) |
| BR (1) | BRPI0413349A (es) |
| CA (1) | CA2534529A1 (es) |
| MX (1) | MXPA06001480A (es) |
| PA (1) | PA8608601A1 (es) |
| PE (1) | PE20050337A1 (es) |
| SV (1) | SV2005001840A (es) |
| TW (1) | TW200510351A (es) |
| UY (1) | UY28458A1 (es) |
| WO (1) | WO2005016267A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934091B (zh) * | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| CA2619068A1 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| ES2525229T3 (es) | 2007-02-15 | 2014-12-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolinas como ligandos de TAAR1 |
| PT2385938E (pt) | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
| CN104603118B (zh) * | 2012-05-31 | 2017-10-03 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物 |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| SG11202108079RA (en) | 2019-01-24 | 2021-08-30 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| CN113651805B (zh) * | 2021-07-19 | 2023-07-25 | 安徽医科大学 | 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094462A (en) * | 1961-09-18 | 1963-06-18 | Mcneilab Inc | Therapeutic reaction complex for muscle relaxation |
| US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
| GB1264258A (es) * | 1970-10-10 | 1972-02-16 | ||
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| KR20000005291A (ko) * | 1996-06-25 | 2000-01-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도 |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| WO2000059285A2 (en) * | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| BR0315158A (pt) * | 2002-10-09 | 2005-08-16 | Pfizer Prod Inc | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos |
| AP2005003274A0 (en) * | 2002-10-09 | 2005-06-30 | Galloway & Co | Thiazole compounds for the treatment of neurodegenerative disorders |
| PL211061B1 (pl) * | 2002-12-23 | 2012-04-30 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, ich zastosowanie i kompozycja farmaceutyczna |
| EP1587799B1 (en) * | 2003-01-13 | 2008-03-12 | F. Hoffmann-La Roche Ag | Benzoxazole derivatives and their use as adenosine receptor ligands |
-
2004
- 2004-08-04 BR BRPI0413349-8A patent/BRPI0413349A/pt not_active IP Right Cessation
- 2004-08-04 CA CA002534529A patent/CA2534529A1/en not_active Abandoned
- 2004-08-04 EP EP04779943A patent/EP1653952A4/en not_active Withdrawn
- 2004-08-04 WO PCT/US2004/025023 patent/WO2005016267A2/en active Application Filing
- 2004-08-04 JP JP2006522669A patent/JP2007501244A/ja not_active Withdrawn
- 2004-08-04 MX MXPA06001480A patent/MXPA06001480A/es active IP Right Grant
- 2004-08-05 TW TW093123538A patent/TW200510351A/zh unknown
- 2004-08-05 US US10/911,869 patent/US7112599B2/en not_active Expired - Fee Related
- 2004-08-06 UY UY28458A patent/UY28458A1/es not_active Application Discontinuation
- 2004-08-06 PA PA20048608601A patent/PA8608601A1/es unknown
- 2004-08-06 PE PE2004000763A patent/PE20050337A1/es not_active Application Discontinuation
- 2004-08-06 AR ARP040102804A patent/AR046327A1/es unknown
- 2004-08-09 SV SV2004001840A patent/SV2005001840A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20050337A1 (es) | 2005-06-06 |
| TW200510351A (en) | 2005-03-16 |
| EP1653952A4 (en) | 2007-04-04 |
| BRPI0413349A (pt) | 2006-10-10 |
| AR046327A1 (es) | 2005-12-07 |
| MXPA06001480A (es) | 2006-05-15 |
| US7112599B2 (en) | 2006-09-26 |
| WO2005016267A2 (en) | 2005-02-24 |
| EP1653952A2 (en) | 2006-05-10 |
| SV2005001840A (es) | 2005-11-04 |
| WO2005016267A3 (en) | 2005-04-21 |
| US20050032859A1 (en) | 2005-02-10 |
| PA8608601A1 (es) | 2005-03-03 |
| JP2007501244A (ja) | 2007-01-25 |
| CA2534529A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2005000040A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| UY28450A1 (es) | Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos. | |
| UY28011A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| ECSP066888A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
| BRPI0509504A (pt) | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos | |
| UY28458A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
| CR9815A (es) | Compuestos de imidazol para el tratamiento de transtornos neurologicos | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
| DOP2004000970A (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
| DOP2004000982A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
| DOP2004000966A (es) | Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos | |
| DOP2006000200A (es) | Compuestos de imidazol para el tratamiento de trastonos neurologicos | |
| CU23591B7 (es) | Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos | |
| BRPI0402756A (pt) | método para o tratamento de distúrbios cognitivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150604 |